research use only
Cat.No.S1099
| Related Targets | EGFR VEGFR JAK PDGFR FGFR Src HIF FLT HER2 Bcr-Abl |
|---|---|
| Other FLT3 Inhibitors | UNC2025 Dovitinib (TKI-258) Dovitinib (TKI258) Lactate monohydrate Tandutinib (MLN518) KW-2449 ENMD-2076 AST-487 (NVP-AST487) TCS 359 FLT3-IN-2 FF-10101 |
|
In vitro |
DMSO
: 50 mg/mL
(92.99 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 537.66 | Formula | C25H27N7O3S2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1370256-78-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=CC=C(C=C1)NC(=O)NC2=NN=C(S2)SC3=NC=NC4=C3C=CC(=C4)OCCCN5CCOCC5 | ||
| Targets/IC50/Ki |
FLT3
(Cell-free assay) 10 nM
|
|---|---|
| In vitro |
SKLB4771 (FLT3-IN-1) just weakly inhibits Aurora A, FMS, FLT4, and c-Kit (IC50s: 1.5 μM, 2.8 μM, 3.7 μM, and 6.8 μM, respectively). It displays almost no inhibitory activity against the other 13 selected protein kinases. This compound potently inhibits the growth of MV4-11 cells that express FLT3-ITD, with an IC50 value of 0.006 μM. It just exhibits very weak inhibitory activity against human T lymphoma Jurkat cells, human Burkitt’s lymphoma Ramos cells, human lung cancer PC-9 and H292 cells, and human epithelial carcinoma A431 cells (IC50: 3.05 μM, 6.25 μM, 3.72 μM, 6.94 μM, and 8.91 μM, respectively).. |
| In vivo |
In the MV4-11 xenograft model, treatment with SKLB4771 (FLT3-IN-1) at 100 mg/kg/d results in rapid and complete tumor regression in all mice of this group. At doses of 20 mg/kg/d and 40 mg/kg/d, it significantly slows down tumor growth, with inhibition rates of 66% and 84%, respectively. Throughout the experiment, no significant weight loss or other obvious signs of toxicity were observed in any of the treated mice. Tumor tissues from groups receiving this compound showed significantly fewer Ki67 (tumor mitotic index)-positive cells. TUNEL data indicated a time-dependent increase in the percentage of apoptotic cells. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.